

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**新琪安集團股份有限公司**  
**(Newtrend Group Holding Co., Ltd.)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2573)**

**1. RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;**  
**2. APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;**  
**AND**  
**3. CHANGE IN COMPOSITION OF BOARD COMMITTEES**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Newtrend Group Holding Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

**RESIGNATION OF DIRECTOR**

The Board hereby announces that Dr. Li Ling (“**Dr. Li**”) has resigned as an independent non-executive Director (“**Independent Non-Executive Director**”), a member of each of the audit Committee (“**Audit Committee**”) and the nomination Committee (“**Nomination Committee**”) of the Company in order to devote more time to other business engagements which has taken effect from 14 May 2026.

Dr. Li has confirmed that she has no disagreement with the Board and that there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Li for her contributions to the Company during her tenure.

## APPOINTMENT OF DIRECTOR

The Board further announces that it has resolved to appoint Dr. Zhang Xi (張茜) (“**Dr. Zhang**”) as Independent Non-Executive Director, with effect from 14 May 2026. Her term of office shall expire at the forthcoming AGM of the Company, and she shall be eligible for re-election upon retirement.

The following is the biography of Dr. Zhang:

**Dr. Zhang Xi (張茜)**, aged 37, holds a doctorate degree in Food Science from Cornell University in the United States. She is currently the deputy general manager of GENEDART Biotechnology Co., Ltd. (基茵達生物技術(北京)有限公司), where she oversees the marketing, quality management, and product and solution centers. Dr. Zhang possesses extensive expertise in product research and development, technology transfer and commercialization within the human and animal nutrition and health sectors. Prior to her current role, she served as the R&D director at Shenzhen Kexing Tianhe Biotechnology Co., Ltd.\* (深圳科興天合生物科技有限公司) and medical director at Kexing Biopharm Co., Ltd.\* (科興生物製藥有限公司), where she was responsible for product application development, regulatory registration and scientific collaboration. Earlier in her career, Dr. Zhang worked as a food scientist at Lawrence Foods in the United States and as a research assistant at the U.S. Food and Drug Administration (“**FDA**”), where she contributed to the revision of the Food Allergen Labeling and Consumer Protection Act in the United States. Dr. Zhang is a Shenzhen Overseas High-Level Talent and has been awarded the Distinguished Research Collaboration Award by the FDA. She has published multiple papers in international peer-reviewed journals such as the Journal of Agricultural and Food Chemistry and is an inventor on numerous Chinese patents related to fungal biomass fermentation and plant-based protein processing.

Dr. Zhang has entered into a letter of appointment with the Company in connection with her appointment as Independent Non-Executive Director. Her directorship is subject to retirement by rotation and re-election at the general meetings in accordance with the articles of association of the Company. She will receive an annual Director’s emoluments and allowances of RMB62,000. Such remuneration has been determined with the recommendation of the remuneration committee of the Company and after taking into account her personal background, duties and responsibilities to be undertaken at the Company, as well as prevailing market conditions.

Save as disclosed above, as at Latest Practicable Date, Dr. Zhang has confirmed that she (i) does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) does not have any interest in any shares or underlying shares or any debentures of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years nor other major appointments and professional qualifications; and (iv) does not hold any other positions with the Company’s subsidiaries.

Save as disclosed above, there are no other matters that need to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor any other matters relating to the appointment of Dr. Zhang that need to be brought to the attention of the shareholders of the Company.

Prior to the taking effect of Dr. Zhang's appointment, she has obtained legal advice from a law firm qualified to provide legal opinions on Hong Kong law on 12 May 2026 pursuant to Rule 3.09D of the Listing Rules, and confirmed her understanding of the duties and obligations as a director of the Company. Dr. Zhang also confirmed that (i) she meets the independence criteria set out in Rule 3.13 of the Listing Rules; (ii) she has no past or present financial or other interests in the business of the Group, nor any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence as an Independent Non-Executive Director at the time of her appointment.

The Board takes this opportunity to welcome Dr. Zhang to join the Board.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board further announces that with effect from 14 May 2026, Dr. Zhang shall also be appointed as a member of each of the Audit Committee and the Nomination Committee.

Following the above changes:

The Audit Committee will consist of three Independent Non-Executive Directors, namely Dr. Song Jingjin, Mr. Lo Kwing Yu and Dr. Zhang. Dr. Song Jingjin will serve as the chairman of the Audit Committee.

The Nomination Committee will consist of one executive Director and two Independent Non-Executive Directors, namely Mr. Wang Xiaoqiang, Dr. Song Jingjin and Dr. Zhang. Mr. Wang Xiaoqiang will serve as the chairman of the Nomination Committee.

By Order of the Board  
**Newtrend Group Holding Co., Ltd.**  
**Wang Xiaoqiang**

*Chairman of the Board and Executive Director*

Jiangxi, China, 14 May 2026

*As at the date of this announcement, the Board of the Company comprises Mr. Wang Xiaoqiang, Mr. Wang Hao, Ms. Chen Lijun, Mr. Wu Dingfeng and Ms. Zuo Yue as executive Directors; Mr. Xiao Fan as non-executive Director; and Dr. Song Jingjin, Dr. Zhang Xi and Mr. Lo Kwing Yu as Independent Non-Executive Directors.*